iMedic.health

MEK inhibitor (antineoplastic): Class Overview and Comparison

Quick answer: MEK inhibitor (antineoplastic) are a class of medicines used for specific therapeutic indications. iMedic covers 3 mek inhibitor (antineoplastic) substances. Below is a comparison table linking to detailed pages for each.

MEK inhibitor (antineoplastic) on iMedic (3 substances)

Substance Primary indications Mechanism Common dose
CotellicMetastatic melanoma with BRAF V600 mutation (combined with vemurafenib)Selective inhibitor of MEK1 and MEK2 kinases in the MAPK pathway, blocking tumor60 mg once daily for 21 days followed by 7 days off
MekinistBRAF V600-mutated melanoma, Non-small cell lung cancerSelective inhibitor of MEK1/MEK2 kinases blocking MAPK pathway signaling in BRAF2 mg once daily (trametinib)
MektoviBRAF V600-mutated melanoma, BRAF V600E-mutated colorectal cancerSelective MEK1/MEK2 kinase inhibitor used in combination with encorafenib for BR45 mg twice daily (binimetinib)

About MEK inhibitor (antineoplastic)

MEK inhibitor (antineoplastic) share a common mechanism of action and clinical use. Specific dosing, side effects, contraindications, and drug interactions vary between individual substances within the class. Click any substance above for full prescribing information and patient guidance.

Common considerations across the class

Always consult the prescribing information for the specific medicine prescribed and discuss with your clinician.

Medical disclaimer: This tool provides educational information for general reference. It is not a substitute for professional medical advice, diagnosis, or treatment. Always discuss your individual situation with a qualified healthcare provider.

Frequently asked questions

What are MEK inhibitor (antineoplastic)?

MEK inhibitor (antineoplastic) are medicines that share a common mechanism of action used for specific therapeutic indications. iMedic currently covers 3 substances in this class with detailed pages for each.

Are all MEK inhibitor (antineoplastic) interchangeable?

No. While medicines in the same class share a mechanism, they differ in potency, dosing, drug interactions, and tolerability. Switching between them is a clinical decision based on individual response, side effects, and treatment goals.

How do I choose between different MEK inhibitor (antineoplastic)?

Selection depends on the specific clinical indication, patient factors (age, comorbidities, kidney/liver function, other medications), tolerability of side effects, cost, and clinician preference. This is a prescribing decision.

Are MEK inhibitor (antineoplastic) available as generics?

Most well-established class members are available as generic alternatives, often substantially less expensive than brand-name versions while clinically equivalent. Newer members may still be brand-only.

Last reviewed: by iMedic Medical Editorial Team. Our editorial process.